Evaluation of genetic mutations associated with mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: A systematic review

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Georghiou, Sophia B ^a   Magana, Marisa ^b   Garfein, Richard S ^c   Catanzaro, Donald G ^d   Catanzaro, Antonino ^b   Rodwell, Timothy C ^c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UCSD MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; EIS PROTEIN, MYCOBACTERIUM TUBERCULOSIS; METHYLTRANSFERASE; TLYA PROTEIN, MYCOBACTERIUM TUBERCULOSIS;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DIAGNOSTIC VALUE; DISEASE MARKER; EIS GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GIDB GENE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; RRS GENE; SENSITIVITY AND SPECIFICITY; TLYA GENE; DRUG EFFECT; GENETICS; HUMAN; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION; PROMOTER REGION; REVIEW;

MYCOBACTERIUM TUBERCULOSIS;

AMIKACIN; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CAPREOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; KANAMYCIN; METHYLTRANSFERASES; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PROMOTER REGIONS, GENETIC; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84859054656     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033275     Document Type: Article

References (78)

1. Organization WH (2011) Global Tuberculosis Control Geneva World Health Organization.
2. Organization WH (2011) WHO: Tuberculosis.
3. Raviglione MC, Smith IM, (2007) XDR tuberculosis-implications for global public health. N Engl J Med 356: 656-659.
4. Organization WH (2010) Global Tuberculosis Control Geneva World Health Organization.
5. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, et al. (2010) Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 16: 264-271.
6. Pfyffer GE, Bonato DA, Ebrahimzadeh A, Gross W, Hotaling J, et al. (1999) Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 37: 3179-3186.
7. Shah NS, Richardson J, Moodley P, Moodley S, Babaria P, et al. (2011) Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis 17: 510-513.
8. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S, (2005) Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 43: 3699-3703.
9. Kiet VS, Lan NT, An DD, Dung NH, Hoa DV, et al. (2010) Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 48: 2934-2939.
10. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W, (2010) Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 48: 1683-1689.
11. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 1005-1015.
12. Watterson SA, Wilson SM, Yates MD, Drobniewski FA, (1998) Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol 36: 1969-1973.
13. Drobniewski FA, Wilson SM, (1998) The rapid diagnosis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis-a molecular story. J Med Microbiol 47: 189-196.
14. Alcaide F, Coll P, (2011) Advances in rapid diagnosis of tuberculosis disease and anti-tuberculous drug resistance. Enferm Infecc Microbiol Clin 29 (Suppl 1): 34-40.
15. Magnet S, Blanchard JS, (2005) Molecular insights into aminoglycoside action and resistance. Chem Rev 105: 477-498.
16. Trnka L, Smith DW, (1970) Proteosynthetic activity of isolated ribosomes of Mycobacteria and its alteration by rifampicin and related tuberculostatic drugs. Antibiot Chemother 16: 369-379.
17. Blaschitz M, Hasanacevic D, Hufnagl P, Hasenberger P, Pecavar V, et al. (2011) Real-time PCR for single-nucleotide polymorphism detection in the 16S rRNA gene as an indicator for extensive drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 66: 1243-1246.
18. Feuerriegel S, Cox HS, Zarkua N, Karimovich HA, Braker K, et al. (2009) Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 53: 3353-3356.
19. Honore N, Marchal G, Cole ST, (1995) Novel mutation in 16S rRNA associated with streptomycin dependence in Mycobacterium tuberculosis. Antimicrob Agents Chemother 39: 769-770.
20. Johansen SK, Maus CE, Plikaytis BB, Douthwaite S, (2006) Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2′-O-methylations in 16S and 23S rRNAs. Mol Cell 23: 173-182.
21. Suzuki M, Funatsu T, Tanaka H, Usuda S, (1998) YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi. Jpn J Pharmacol 77: 177-183.
22. Alangaden GJ, Kreiswirth BN, Aouad A, Khetarpal M, Igno FR, et al. (1998) Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42: 1295-1297.
23. Maus CE, Plikaytis BB, Shinnick TM, (2005) Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49: 3192-3197.
24. Maus CE, Plikaytis BB, Shinnick TM, (2005) Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49: 571-577.
25. Kruuner A, Jureen P, Levina K, Ghebremichael S, Hoffner S, (2003) Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 2971-2973.
26. Sugawara I, Zhang J, Li C, (2009) Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin. Indian J Exp Biol 47: 520-522.
27. Ioerger TR, Koo S, No EG, Chen X, Larsen MH, et al. (2009) Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One 4: e7778.
28. Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, et al. (2009) High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 53: 5064-5068.
29. Hillemann D, Rusch-Gerdes S, Richter E, (2009) Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 47: 1767-1772.
30. Evans J, Segal H, (2010) Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis. J Antimicrob Chemother 65: 897-900.
31. Perdigao J, Macedo R, Malaquias A, Ferreira A, Brum L, et al. (2010) Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother 65: 224-227.
32. Via LE, Cho SN, Hwang S, Bang H, Park SK, et al. (2010) Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol 48: 402-411.
33. Leung KL, Yip CW, Yeung YL, Wong KL, Chan WY, et al. (2010) Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs. J Appl Microbiol 109: 2087-2094.
34. Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, et al. (2010) Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. Antimicrob Agents Chemother 54: 4789-4793.
35. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, et al. (2011) Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55: 2032-2041.
36. Huang WL, Chi TL, Wu MH, Jou R, (2011) Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 49: 2502-2508.
37. Engstrom A, Perskvist N, Werngren J, Hoffner SE, Jureen P, (2011) Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 66: 1247-1254.
38. Sirgel FA, Tait M, Warren RM, Streicher EM, Bottger EC, et al. (2011) Mutations in the rrs A1401G Gene and Phenotypic Resistance to Amikacin and Capreomycin in Mycobacterium tuberculosis. Microb Drug Resist.
39. Zaunbrecher MA, Sikes RD, Metchock B, Shinnick TM, Posey JE, (2009) Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 106: 20004-20009.
40. Sun Z, Zhang J, Zhang X, Wang S, Zhang Y, et al. (2008) Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 31: 115-121.
41. Camus JC, Pryor MJ, Medigue C, Cole ST, (2002) Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 148: 2967-2973.
42. Johnson R, Streicher EM, Louw GE, Warren RM, van Helden PD, et al. (2006) Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 8: 97-111.
43. Valvatne H, Syre H, Kross M, Stavrum R, Ti T, et al. (2009) Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing. J Antimicrob Chemother 64: 694-701.
44. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, et al. (1993) Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341: 647-650.
45. Ramaswamy SV, Reich R, Dou SJ, Jasperse L, Pan X, et al. (2003) Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 1241-1250.
46. Sharma D, Cukras AR, Rogers EJ, Southworth DR, Green R, (2007) Mutational analysis of S12 protein and implications for the accuracy of decoding by the ribosome. J Mol Biol 374: 1065-1076.
47. Wong SY, Lee JS, Kwak HK, Via LE, Boshoff HIM, et al. (2011) Mutations in gidB Confer Low-Level Streptomycin Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 55: 2515-2522.
48. Springer B, Kidan YG, Prammananan T, Ellrott K, Bottger EC, et al. (2001) Mechanisms of streptomycin resistance: selection of mutations in the 16S rRNA gene conferring resistance. Antimicrob Agents Chemother 45: 2877-2884.
49. O'Grady J, Maeurer M, Mwaba P, Kapata N, Bates M, et al. (2011) New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med 17: 134-141.
50. Miotto P, Piana F, Penati V, Canducci F, Migliori GB, et al. (2006) Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. J Clin Microbiol 44: 2485-2491.
51. Cavusoglu C, Turhan A, Akinci P, Soyler I, (2006) Evaluation of the Genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates. J Clin Microbiol 44: 2338-2342.
52. Somoskovi A, Dormandy J, Mitsani D, Rivenburg J, Salfinger M, (2006) Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. J Clin Microbiol 44: 4459-4463.
53. Hillemann D, Rusch-Gerdes S, Richter E, (2007) Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 45: 2635-2640.
54. Ling DI, Zwerling AA, Pai M, (2008) GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 32: 1165-1174.
55. Lacoma A, Garcia-Sierra N, Prat C, Ruiz-Manzano J, Haba L, et al. (2008) GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 46: 3660-3667.
56. Evans J, Stead MC, Nicol MP, Segal H, (2009) Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa. J Antimicrob Chemother 63: 11-16.
57. Nikolayevskyy V, Balabanova Y, Simak T, Malomanova N, Fedorin I, et al. (2009) Performance of the Genotype MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation. BMC Clin Pathol 9: 2.
58. Miotto P, Piana F, Cirillo DM, Migliori GB, (2008) Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol 46: 393-394.
59. Kontsevaya I, Mironova S, Nikolayevskyy V, Balabanova Y, Mitchell S, et al. (2011) Evaluation of two molecular assays for rapid detection of mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and-multidrug-resistance Settings. J Clin Microbiol 49: 2832-2837.
60. Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, et al. (2011) Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 8: e1001061.
61. van Ingen J, Simons S, de Zwaan R, van der Laan T, Kamst-van Agterveld M, et al. (2010) Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 48: 2749-2753.
62. Zhao MC, Bao L, Wu YH, Long Y, Zeng XW, et al. (2004) [Study on the gene mutation of quinolone-resistant Mycobacterium tuberculosis isolated from Sichuan Province]. Sichuan Da Xue Xue Bao Yi Xue Ban 35: 313-315.
63. Djelouadji Z, Henry M, Bachtarzi A, Foselle N, Raoult D, et al. (2009) Pyrosequencing identification of Mycobacterium tuberculosis W-Beijing. BMC Res Notes 2: 239.
64. Bravo LT, Tuohy MJ, Ang C, Destura RV, Mendoza M, et al. (2009) Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. J Clin Microbiol 47: 3985-3990.
65. Isola D, Pardini M, Varaine F, Niemann S, Rusch-Gerdes S, et al. (2005) A Pyrosequencing assay for rapid recognition of SNPs in Mycobacterium tuberculosis embB306 region. J Microbiol Methods 62: 113-120.
66. Jureen P, Engstrand L, Eriksson S, Alderborn A, Krabbe M, et al. (2006) Rapid detection of rifampin resistance in Mycobacterium tuberculosis by Pyrosequencing technology. J Clin Microbiol 44: 1925-1929.
67. Wakata A, Miyamae Y, Sato S, Suzuki T, Morita T, et al. (1998) Evaluation of the rat micronucleus test with bone marrow and peripheral blood: summary of the 9th collaborative study by CSGMT/JEMS. MMS. Collaborative Study Group for the Micronucleus Test. Environmental Mutagen Society of Japan. Mammalian Mutagenicity Study Group. Environ Mol Mutagen 32: 84-100.
68. Varma-Basil M, El-Hajj H, Colangeli R, Hazbon MH, Kumar S, et al. (2004) Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates from India and Mexico by a molecular beacon assay. J Clin Microbiol 42: 5512-5516.
69. Nebenzahl-Guimaraes H, (2009) Recent patents on DNA sequences and diagnostic methods for the identification and strain differentiation of Mycobacterium tuberculosis. Recent Pat DNA Gene Seq 3: 172-176.
70. Stavrum R, Myneedu VP, Arora VK, Ahmed N, Grewal HM, (2009) In-depth molecular characterization of Mycobacterium tuberculosis from New Delhi-predominance of drug resistant isolates of the 'modern' (TbD1) type. PLoS One 4: e4540.
71. Banerjee R, Allen J, Lin SY, Westenhouse J, Desmond E, et al. (2010) Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California. J Clin Microbiol 48: 3779-3781.
72. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W, (2010) Xpert((R)) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn 10: 937-946.
73. Organization WH (2008) Guidelines for the programmatic management of drug-resistant tuberculosis.
74. Kleeberg HHKH, HP, (1980) Susceptibility testing. Laboratory manual of tuberculosis methods 2.
75. Kent PTaK, GP, (1985) Public health mycobacteriology: a guide for level III laboratory.
76. Kam KM, Sloutsky A, Yip CW, Bulled N, Seung KJ, et al. (2010) Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 14: 282-288.
77. Jureen P, Angeby K, Sturegard E, Chryssanthou E, Giske CG, et al. (2010) Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol 48: 1853-1858.
78. Kekkaku, (1997) Drug susceptibility testing of Mycobacterium tuberculosis: a proportion method using Ogawa egg medium. Committee for Laboratory Services of the Japanese Society for Tuberculosis 72: 597-598.